News Home

Is Acasti Pharma Inc (ACST) a Leader in the Biotechnology Industry?

Tuesday, December 28, 2021 01:48 PM | InvestorsObserver Analysts
Is Acasti Pharma Inc (ACST) a Leader in the Biotechnology Industry?

A rating of 94 puts Acasti Pharma Inc (ACST) near the top of the Biotechnology industry according to InvestorsObserver. Acasti Pharma Inc's score of 94 means it scores higher than 94% of stocks in the industry. Acasti Pharma Inc also received an overall rating of 62, putting it above 62% of all stocks. Biotechnology is ranked 91 out of the 148 industries.

Overall Score - 62
ACST has an Overall Score of 62. Find out what this means to you and get the rest of the rankings on ACST!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 62 means the stock is more attractive than 62 percent of stocks. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Acasti Pharma Inc Stock Today?

Acasti Pharma Inc (ACST) stock is trading at $1.25 as of 1:39 PM on Tuesday, Dec 28, a loss of -$0.09, or -6.72% from the previous closing price of $1.34. The stock has traded between $1.22 and $1.37 so far today. Volume today is low. So far 1,642,392 shares have traded compared to average volume of 2,501,800 shares. Click Here to get the full Stock Report for Acasti Pharma Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App